FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 62181

Company■ Unclear/unknown

New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim

KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-02 12:00 UTC
LAST UPDATE2026-10-02 12:00 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

A Phase 3 obesity trial for survodutide expands the competitive GLP-1 landscape long term.

New obesity trial intensifies GLP-1 competition
CATALYST TO WATCH

Trial enrollment and efficacy data

MAIN RISK

Trial may fail or lag competitors

FULL DISPATCH

Sponsor: Boehringer Ingelheim; Status: Not Yet Recruiting; Conditions: Obesity; Interventions: Survodutide; Enrollment: 350 (estimated); First posted: 2026-10-02; NCT: NCT07855900

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01clinicaltrialsclinicaltrials.gov · PRIMARY2026-10-02 12:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.